{
  "ticker": "ATX",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02964933",
  "id": "02964933",
  "pages": 2,
  "price_sensitive": false,
  "date": "20250702",
  "time": "0942",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250702/pdf/06lcl2f18z4v40.pdf",
  "summary": "**Clinical Trial Update Summary (Material Information Only):**  \n\n- **Additional confirmed partial response (PR)** in Phase 1b/2a ACCENT trial (narmafotinib + gemcitabine/Abraxane\u00ae for advanced pancreatic cancer).  \n- **Total confirmed PRs**: 16 out of 55 patients (29% objective response rate).  \n- **Patients remaining in trial**: 20.  \n- **Trial progression**: Phase 2a evaluating efficacy endpoints (ORR, PFS, OS).  \n\n*No direct capital markets or trading impact identified.*",
  "usage": {
    "prompt_tokens": 1199,
    "completion_tokens": 120,
    "total_tokens": 1319,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-02T00:00:50.359191"
}